[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-nodule\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-nodule":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,78,106,136,168,195,226,257,282,315,339,363],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100587083","european-real-world-registry-for-use-of-the-ion-endoluminal-system-100587083",false,"NCT06923774","European Real-World Registry for Use of the Ion Endoluminal System","A European Multi-Center, Prospective, Single-Arm, Observational Study to Evaluate Real-World Outcomes for the Ion Endoluminal System","Inclusion Criteria:\n\n* Patient is aged 18 years or older at time of consent.\n* Patient is planned to undergo a lung lesion biopsy(s) and\u002For localization procedure(s) utilizing the Ion endoluminal system.\n* Patient is willing and able to give written informed consent for clinical study participation.\n\nExclusion Criteria:\n\n* Patient is participating in an interventional research study or research study with investigational agents with an unknown safety profile that would interfere with participation in this study or study results.\n* Female patient that is pregnant or breast feeding as determined by standard site practices.\n* Patient is legally incapacitated or in a legal\u002Fcourt ordered institution or is part of a known vulnerable population, including but not limited to dependency on the sponsor, hospital or study doctor.\n* Patient is not willing to comply with post-procedure study participation requirements.\n* Investigator, in their professional opinion, has decided that it is in the patient's best interest to not participate in the clinical study.","ALL","18 Years",{"count":19,"type":20},1200,"ESTIMATED","24 Months","OBSERVATIONAL","The objective of this study is to collect collect real-world data for the Ion endoluminal system.",[25,26],"Pulmonary Nodule","Lung Cancer",[28,29,30,31],"Biopsy","Bronchoscopy","pulmonary biopsy","pulmonary nodule localization","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2025-09-09",{"date":40,"type":20},"2029-10",{"name":42,"class":43},"Intuitive Surgical","INDUSTRY",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100644328","robotic-bronchoscopy-with-cbct-image-fusion-for-pulmonary-nodule-diagnosis-in-people-living-with-hiv-100644328","NCT07663656","Robotic Bronchoscopy With CBCT Image Fusion for Pulmonary Nodule Diagnosis in People Living With HIV","Clinical Application and Promotion of Full-Situational Awareness Bronchoscopic Robot Combined With CBCT-Based Multimodal Image Fusion for the Diagnosis and Management of Pulmonary Nodules in People Living With HIV: A Multicenter Open-Label Controlled Study","Inclusion Criteria:\n\n1. Confirmed diagnosis of HIV infection; on stable antiretroviral therapy (ART) for ≥6 months with plasma HIV viral load \\\u003C50 copies\u002FmL.\n2. Presence of at least one pulmonary nodule ≤3 cm in maximum diameter on thin-section CT; radiological features suggestive of malignancy (e.g., part-solid or solid nodule with spiculation, lobulation, or vessel convergence) with estimated pretest probability of malignancy ≥50%.\n3. Age 18-70 years.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n5. Life expectancy ≥6 months.\n6. Voluntary written informed consent obtained prior to any study procedure; willingness and ability to comply with scheduled visits, procedures, and follow-up requirements.\n\nExclusion Criteria:\n\n1. Active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia requiring acute treatment at the time of screening.\n2. Coagulation disorder: International Normalized Ratio (INR) \\>1.5 or platelet count \\\u003C50 × 10\\^9\u002FL.\n3. Prior definitive treatment for the target pulmonary nodule (e.g., surgical resection, radiotherapy, ablation, or systemic anti-tumor therapy).\n4. Unstable ART status: not on continuous ART or HIV viral load ≥50 copies\u002FmL within 3 months prior to enrollment.\n5. Target lesion already diagnosed definitively by previous percutaneous biopsy or surgical pathology.\n6. Severe cardiopulmonary dysfunction:\n\n   * Forced Expiratory Volume in 1 second (FEV1) \\\u003C50% predicted; or\n   * New York Heart Association (NYHA) Class III-IV heart failure.\n7. Pregnancy or breastfeeding.\n8. Participation in another interventional clinical trial within the past 3 months.\n9. Inability to complete follow-up (e.g., no fixed residence, unstable contact information).\n10. Any other condition that, in the investigator's judgment, would make the participant unsuitable for enrollment or pose unacceptable risk (including significant airway abnormality preventing safe navigation).","70 Years",{"count":54,"type":20},100,"INTERVENTIONAL",[57],"NA","This multicenter study evaluates a full-situational awareness robotic bronchoscopy system combined with CBCT-based multimodal image fusion for diagnosing lung nodules in people living with HIV (PLWH).\n\nLung nodules are small lesions that may be benign or cancerous. In PLWH, accurate diagnosis is especially important but challenging. In this study, participants will be assigned to one of two groups:\n\n* Experimental group: Robotic bronchoscopy with real-time full-situational awareness and CBCT image fusion;\n* Control group: Electromagnetic navigation-guided bronchoscopy combined with radial endobronchial ultrasound (EBUS).\n\nIn both groups, rapid on-site cytologic evaluation (ROSE) will be performed to confirm tissue adequacy. For participants confirmed to have lung cancer and meeting safety criteria, an exploratory transbronchial cryoablation will be performed during the same procedure.\n\nThe study aims to compare diagnostic accuracy and safety between the two approaches and to explore the feasibility of immediate cryoablation for early-stage lung cancer in PLWH.",[60,25],"HIV Infections",[62,63,64,25,65,66],"Full-Situational Awareness Robotic Bronchoscopy","Cone-Beam CT","HIV","Cryoablation","Diagnostic Yield","NOT_YET_RECRUITING","2026-06-17",{"date":70,"type":36},"2026-06-23",{"date":72,"type":20},"2026-07",{"date":74,"type":20},"2028-03",{"name":76,"class":77},"wu qingguo","OTHER_GOV",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":55,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100632357","phase-4-effect-of-intercostal-nerve-block-with-liposomal-bupivacaine-on-quality-of-recovery-in-vats-partial-pneumonectomy-100632357","NCT07512635","Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Quality of Recovery in VATS Partial Pneumonectomy","Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Postoperative Quality of Recovery in Patients Undergoing Video-assisted Thoracoscopic Partial Pneumonectomy","Inclusion Criteria:\n\n* Patients scheduled for thoracic surgery under general anesthesia via thoracoscopic approach;\n* Age 18-65 years;\n* Classified as Grade I-II by the American Society of Anesthesiologists (ASA).\n\nExclusion Criteria:\n\n* History of local anesthetic allergy.\n* Chronic opioid users.\n* Contraindications for nerve block, including infection at the puncture site and coagulation disorders;\n* Language communication impairment.\n* Other conditions unsuitable for inclusion in the trial.","65 Years",{"count":87,"type":20},96,[89],"PHASE4","Video-assisted thoracoscopic surgery (VATS) is a minimally invasive approach for partial pneumonectomy, but postoperative pain remains a major challenge affecting recovery. Intercostal nerve block (ICNB) with conventional local anesthetics provides limited duration of analgesia, often insufficient to cover the peak pain period after surgery. Liposomal bupivacaine is a long-acting formulation designed to provide extended analgesia up to 72 hours. This study aims to evaluate the effect of preoperative ICNB with liposomal bupivacaine compared with conventional bupivacaine hydrochloride on postoperative quality of recovery in patients undergoing VATS partial pneumonectomy. The primary outcome is the Quality of Recovery-15 (QoR-15) score at 24 hours postoperatively. We hypothesize that liposomal bupivacaine ICNB results in superior recovery quality compared with conventional bupivacaine, with reduced postoperative pain and opioid consumption.",[25,92],"Liposomal Bupivacaine",[94,95],"Liposomal bupivacaine","Intercostal nerve block",{"date":97,"type":36},"2026-06-18",{"date":99,"type":36},"2026-04-06",{"date":101,"type":20},"2027-04-30",{"name":103,"class":104},"Sanming First Hospital","OTHER",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":105},"100640926","preoperative-decision-making-in-patients-with-pulmonary-nodules-suspected-of-lung-cancer-100640926","NCT07590596","Preoperative Decision-Making in Patients With Pulmonary Nodules Suspected of Lung Cancer","Preoperative Decision-Making Characteristics and Associated Mechanisms in Patients With Pulmonary Nodules Suspected of Lung Cancer","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Adult patients with pulmonary nodules that are highly suspected of malignancy based on clinical and radiological assessment.\n3. No definite pathological diagnosis of lung cancer before enrollment.\n4. Patients who are facing preoperative clinical decision-making with more than one reasonable management option, such as surgery, additional diagnostic evaluation, or follow-up.\n5. Able to understand the study procedures and complete the study questionnaires.\n6. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients without a real clinical decision-making choice regarding the management of the pulmonary nodule.\n2. Patients with severe cognitive impairment or a history of severe psychiatric disease that would interfere with valid questionnaire completion.\n3. Patients who are unable to communicate effectively with the study staff.\n4. Patients who decline to participate or are unable to provide written informed consent.",{"count":114,"type":20},200,"Patients with pulmonary nodules that are highly suspected to be lung cancer often need to make important treatment decisions before a definite pathological diagnosis is available. These decisions may include whether to undergo surgery, whether to continue follow-up, whether to have further diagnostic tests, and how to understand the potential benefits and risks of different management options.\n\nThis prospective observational study aims to describe the preoperative decision-making status of adult patients with pulmonary nodules suspected of lung cancer. The study will assess patients' decision self-efficacy, decisional conflict, shared decision-making experience, and decision regret using standardized questionnaires. It will also explore factors associated with better or worse decision quality, such as demographic characteristics, clinical information, health literacy, doctor-patient communication, family involvement, and emotional status.\n\nNo treatment or intervention will be assigned by the study. Participants will receive routine clinical care, and study data will be collected mainly through questionnaires before surgery or during the preoperative period. The findings may help clinicians identify patients who need additional decision support and improve communication during preoperative decision-making for suspected lung cancer.",[25,117,118],"Suspected Lung Cancer","Preoperative Decision-Making",[120,121,122,123,124,25,117,125,118,126],"Shared Decision Making","Decisional Conflict","Decision Self-Efficacy","Decision Quality","Decision Regret","Thoracic Surgery","Patient-Centered Care","2026-05-14",{"date":129,"type":36},"2026-05-18",{"date":131,"type":20},"2026-05",{"date":133,"type":20},"2027-07-31",{"name":135,"class":104},"Sichuan Cancer Hospital and Research Institute",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":55,"phases":146,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":105},"100578334","phase-2-feasibility-of-fluorescence-imaging-with-bevacizumab-800cw-during-bronchoscopy-100578334","NCT06809946","Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy","Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy in Patients With a Pulmonary Lesion Considered to be Malignant - DEFLECT I","DEFLECT I","Inclusion Criteria:\n\n1. Signed informed consent prior to participation in the study.\n2. Age ≥ 18 years.\n3. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).\n4. Patient is considered fit to undergo a diagnostic and\u002For therapeutic bronchoscopy (with or without addition of virtual navigation and\u002For endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.\n\nExclusion Criteria:\n\n1. History of infusion reactions to bevacizumab.\n2. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.\n3. Pregnancy or breast feeding.",{"count":145,"type":20},20,[147],"PHASE2","In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and\u002For lymph nodes considered to be malignant.",[150,151,152,25],"Lung Neoplasms","Pulmonary Neoplasms","Lymph Node Involvement",[154,155,156,157,158],"Fluorescence molecular bronchoscopy","Bevacizumab-800CW","Near-infrared fluorescence imaging","Molecular imaging","Pulmonary nodule","2026-03-24",{"date":161,"type":36},"2026-03-30",{"date":163,"type":20},"2026-08-17",{"date":165,"type":20},"2028-08-17",{"name":167,"class":104},"University Medical Center Groningen",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":55,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100628850","video-double-lumen-tube-for-secondary-pulmonary-resection-100628850","NCT07467005","Video Double-Lumen Tube for Secondary Pulmonary Resection","Video Double-Lumen Tube for Secondary Pulmonary Resection: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* History of previous pulmonary resection.\n* Scheduled for elective pulmonary surgery.\n* Planned to receive a left-sided double-lumen tube.\n* ASA physical status I-III.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Preoperatively predicted difficult airway (Mallampati ≥ III, Cormack-Lehane ≥ III).\n* Acute respiratory distress syndrome (ARDS) or respiratory failure within the past 3 months.\n* Uncontrolled asthma.\n* Confirmed pregnancy or current breastfeeding.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator.",{"count":176,"type":20},500,[57],"During thoracic surgery, double-lumen endotracheal intubation with one-lung ventilation is routinely performed to optimize surgical exposure, facilitate operative manipulation, and prevent iatrogenic lung injury. In patients undergoing repeat pulmonary surgery, prior lung resection may lead to pleural adhesions and tracheobronchial distortion, which substantially increase the difficulty of bronchial intubation. Even with experienced operators, the malposition rate of conventional double-lumen tubes remains high. The video double-lumen tube enables continuous visualization of the trachea and carina during insertion, positioning, and one-lung ventilation, allowing real-time airway monitoring. However, no clinical studies have specifically investigated airway management in patients undergoing redo pulmonary surgery. This study aimed to evaluate the efficacy and safety of the video double-lumen tube during anesthesia in patients undergoing secondary pulmonary resection.",[26,25],[181,182,183,184],"First-attempt Intubation Success Rate","One-lung Ventilation","video double-lumen tube","secondary pulmonary resection","2026-03-09",{"date":187,"type":36},"2026-03-12",{"date":189,"type":20},"2026-03-16",{"date":191,"type":20},"2027-12-05",{"name":193,"class":104},"Zhejiang University",3,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":55,"phases":204,"briefSummary":205,"conditions":206,"keywords":211,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100623358","phase-4-remimazolam-for-bronchoscopy-in-high-risk-patients-100623358","NCT07395596","Remimazolam for Bronchoscopy in High-Risk Patients","A Prospective, Randomized Controlled Clinical Study of the Effect of Remimazolam on the Incidence of Hypoxia in High-risk Patients Undergoing Painless Tracheoscopy","Inclusion Criteria:\n\n* ASA Class Ⅲ - Ⅳ\n* Scheduled for elective painless bronchoscopy -\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients who are uncooperative（e.g. due to mental illness）\n* Patients who are on chronic use of opioids, benzodiazepine - class hypnotics, or antidepressants\n* Patients with a history of allergy to the anesthetics used\n* Patients who are anticipated to have a difficult airway\n* Body mass index（BMI）\\\u003C18.5kg\u002Fm² or \\>30kg\u002Fm²\n* Preoperative oxygen saturation \\\u003C92% while breathing room air\n* Other：Patients who are deemed by the investigator to be unsuitable for participation in this trial",{"count":203,"type":20},360,[89],"Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient, making the patient highly susceptible to respiratory and cardiovascular risks. Among these risks, hypoxia is the most common adverse event.Different drug regimens can be selected for anesthesia under deep sedation. The combination of analgesic agents can help reduce coughing during bronchoscopy. Therefore, we employ a combination of sedative and analgesic drugs for painless bronchoscopy procedures. Among sedatives, propofol is the most commonly used. However, due to its disadvantages, such as respiratory and circulatory depression, we have introduced a novel approach combining remimazolam for sedation. The aim is to investigate whether this new regimen, compared to traditional propofol-based sedation, can reduce the incidence of hypoxia, minimize circulatory depression, and lead to faster postoperative awakening and recovery. Additionally, we hope to observe fewer adverse events, such as perioperative nausea and vomiting, excessive secretions, dizziness, and chills.",[207,25,208,209,210],"Pulmonary Infection","Phthisis","Endotracheal Tumour","Lymphadenectasis",[212,213,214,215],"hypoxia","remimazolam","propofol","fiberoptic bronchoscopy","2026-02-21",{"date":218,"type":36},"2026-02-24",{"date":220,"type":36},"2026-02-09",{"date":222,"type":20},"2026-12",{"name":224,"class":104},"First Affiliated Hospital of Zhejiang University",2,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":55,"phases":236,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":105},"100623339","safety-and-recovery-of-tubeless-strategy-in-uniportal-vats-wedge-resection-100623339","NCT07395349","Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection","Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection: A Single-Center, Prospective Randomized Controlled Study Based On Different Intraoperative Pleural Space Management Strategies","Inclusion Criteria:\n\n1. Age 18 to 80 years\n2. Scheduled to undergo uniportal video-assisted thoracoscopic (VATS) wedge resection\n3. Able to tolerate general anesthesia and single-lung ventilation\n4. Passed a standardized intraoperative water-seal air leak test, confirming absence of persistent air leak before chest closure\n5. Able and willing to provide written informed consent\n6. Able to complete postoperative assessments and 30-day follow-up\n\nExclusion Criteria:\n\n1. Planned anatomical lung resection (segmentectomy or lobectomy) or combined complex thoracic procedures\n2. Extensive pleural adhesions, severe emphysema, bullous lung disease, or other conditions associated with high risk of air leak\n3. Positive intraoperative air leak test indicating persistent air leak\n4. Requirement for additional intraoperative procedures that may significantly affect pleural air leak or lung re-expansion\n5. Conversion to multiport VATS or thoracotomy before randomization\n6. Severe comorbidities or other conditions deemed by the investigators to make participation inappropriate\n7. Inability to complete follow-up or insufficient clinical data","80 Years",{"count":235,"type":20},300,[57],"Brief Summary\n\nThe goal of this clinical trial is to evaluate the safety and recovery outcomes of different tubeless strategies in adult patients undergoing uniportal video-assisted thoracoscopic (VATS) wedge resection who are confirmed to have no persistent air leak intraoperatively.\n\nThe main questions it aims to answer are:\n\nDoes double intraoperative aspiration tubeless strategy reduce the rate of postoperative pleural re-intervention within 30 days compared with single intraoperative aspiration tubeless strategy?\n\nDo different intraoperative pleural space management strategies affect early postoperative recovery quality and pain?\n\nIf there is a comparison group:\n\nResearchers will compare conventional chest tube drainage, single intraoperative aspiration tubeless, and double intraoperative aspiration tubeless strategies to determine their effects on postoperative pleural re-intervention and recovery outcomes.\n\nParticipants will:\n\nUndergo uniportal VATS wedge resection\n\nReceive a standardized intraoperative air leak test before chest closure\n\nBe randomly assigned intraoperatively to one of three pleural space management strategies\n\nComplete postoperative assessments including chest imaging, pain evaluation, and recovery quality questionnaires\n\nBe followed for 30 days after surgery for safety outcomes",[25,239,240],"Pneumothorax","Postoperative Complications",[242,243,244,245,246,247,248],"Uniportal VATS","Wedge Resection","Tubeless","Intraoperative Aspiration","Chest Tube Drainage","Enhanced Recovery After Surgery (ERAS)","Lung Re-expansion","2026-02-06",{"date":220,"type":36},{"date":252,"type":20},"2026-02-28",{"date":254,"type":20},"2026-10-01",{"name":256,"class":104},"The First Affiliated Hospital of Guangzhou Medical University",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":55,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":105},"100622858","the-efficacy-and-safety-of-the-supraglottic-oxygenation-via-nasotracheal-intubation-for-deep-sedation-fiberoptic-bronchoscopy-100622858","NCT07389083","The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Bronchoscopy","The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation Reduce the Incidence of Hypoxia in Patients Undergoing Sedated Fiberoptic Bronchoscopy.","Inclusion Criteria:\n\n* Undergoing fiberoptic bronchoscopy under deep sedation.\n* Written informed consent obtained from the patient or their legal representative.\n* Clear understanding of, and voluntary participation in, the study, with informed-consent form signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 30 kg\u002Fm²\n* Previous history of abnormal recovery from anesthesia\u002Fsurgery\n* History of recurrent epistaxis, nasal bone fracture, nasal polyps, or sinus surgery\n* Chronic use of opioid analgesics, benzodiazepine hypnotics, or antidepressant medications\n* Known allergy to any of the anesthetic agents employed\n* Anticipated difficult airway\n* Increased intracranial pressure\n* Active upper-respiratory-tract infection of the oral, nasal, or pharyngeal regions\n* Severe cardiac insufficiency (functional capacity \\\u003C 4 METs)\n* Severe renal failure requiring dialysis prior to surgery\n* Pre-operative oxygen saturation on room air \\\u003C 92 %\n* Any condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this trial",{"count":265,"type":20},50,[57],"Bronchoscopy is now widely used for the diagnosis and treatment of various respiratory diseases. However, the procedure is highly stimulating and provokes a strong stress response; because the airway is shared, patients are prone to hypoxia. With the growing emphasis on comfortable care, demand for anesthesia during bronchoscopy has increased. Deep sedation is the most common approach, but when administered in the supine position it often causes the tongue base to fall back. Both nasopharyngeal and oropharyngeal airways can relieve this obstruction, yet neither connects seamlessly to an oxygen supply line, resulting in insufficient oxygen delivery.We therefore replaced the nasopharyngeal airway with a wired endotracheal tube (size 4.0 or 4.5) inserted via the nose. This thinner tube couples easily to an oxygen line or ventilator circuit, partially relieves airway obstruction, and allows ample supraglottic oxygenation. The present study was designed to evaluate the feasibility and safety of this modified oxygen-delivery method in patients undergoing deep sedation for bronchoscopy.",[269,25,207],"Hypoxia",[215,269,271,272,273,274],"Deep sedation","supine position","tongue-base fallback","supraglottic oxygenation","2026-01-28",{"date":277,"type":36},"2026-02-05",{"date":279,"type":36},"2025-12-28",{"date":161,"type":20},{"name":224,"class":104},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":291,"conditions":292,"keywords":297,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":105},"100584448","liquid-biopsy-assay-of-ebus-tbna-supernatant-fluid-for-diagnosing-lung-cancer-100584448","NCT06889467","Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer","Validation of Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer: A Feasibility Study","Inclusion Criteria:\n\n* adult (age ≥18 years) patients with high suspicion for NSCLC with thoracic lymph nodes involvement (per clinical judgement and imaging studies), planned for an EBUS-TBNA procedure\n* Subjects with negative EBUS-TBNA results (no evidence of lymph node involvement by tumor according to histology) who will require surgical resection of the thoracic lymph nodes will comprise the final study group\n\nExclusion Criteria:\n\n1. Subjects unable or not willing to provide informed consent for study participation.\n2. Subjects in whom NSCLC will ultimately be ruled out.\n3. Subjects who will not require surgical resection of thoracic lymph nodes, or who will not undergo such procedure in our Medical Center for any reason",{"count":290,"type":20},10,"Background and aim: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the gold standard of lung cancer staging, yet up to 15% of procedures produce inadequate samples for definite diagnosis or staging. In such cases, more invasive surgical procedures are usually considered. Fluid collected during EBUS-TBNA is centrifuged to produce a pellet for cell block histopathological examination , while the supernatant is usually discarded. It has been demonstrated that this supernatant can provide material for next generation sequencing (NGS) mutation analysis using liquid biopsy (LB) technics when the procedure yielded positive results (tumor cells were demonstrated in the aspirate).\n\nWe wish to assess whether LB NGS of the supernatant may provide data regarding lymph nodes involvement in non-small cell lung cancer (NSCLC) in cases with a negative EBUS-TBNA evaluation (no tumor cell identified in the aspirate).\n\nMethods: A prospective feasibility study which will recruit participants with high suspicion for thoracic lymph nodes involvement in NSCLC who will be subjected to EBUS-TBNA. The final study group will comprise of 10 subjects with a negative EBUS-TBNA evaluation (no tumor cell detected) who will require surgical resection of the thoracic lymph nodes.\n\nEBUS-TBNA collected fluid will be centrifuged and separated. Cellular pellets will undergo cytological and histopathological evaluation, including tissue NGS, as usual. Cell-free DNA will be extracted from the supernatant and will undergo separate LB NGS targeted to genes frequently mutated in NSCLC. We will assess the concordance between the positivity of supernatant NGS and surgical lymph nodes staging, and the concordance between supernatant NGS and blood NGS.\n\nExpected results: We expect high concordance between surgical lymph nodes staging and supernatant NGS, that is, genetic mutations would be identified by the supernatant NGS in subjects with lymph nodes involvement by tumor, and not in those without it.\n\nImportance to Medicine: NSCLC is the leading cause of cancer mortality. Improving the effectiveness of EBUS-TBNA may reduce the need for additional invasive procedures, increase accuracy and reduce turnaround time of specimens.",[293,294,295,296,25],"Non Small Cell Lung Cancer","Non Small Cell Lung Cancer (NSCLC)","Lung Cancer (NSCLC)","Lung Cancer - Non Small Cell",[298,299,300,301,302,303,304,305],"Endobronchial ultrasound","Endobronchial ultrasound transcbronchial needle aspiration","EBUS","EBUS-TBNA","staging","lung cancer","non small cell lung cancer","NSCLC","2025-03-22",{"date":308,"type":36},"2025-03-26",{"date":310,"type":36},"2025-01-20",{"date":312,"type":20},"2025-12-31",{"name":314,"class":104},"Barzilai Medical Center",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":55,"phases":323,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":105},"100563226","feasibility-and-safety-of-remote-robotic-bronchoscopy-system-in-diagnosis-of-peripheral-pulmonary-lesions-a-multicenter-randomized-controlled-proof-of-concept-trial-100563226","NCT06613412","Feasibility and Safety of Remote Robotic Bronchoscopy System in Diagnosis of Peripheral Pulmonary Lesions: a Multicenter, Randomized Controlled, Proof-of Concept Trial","Inclusion Criteria:\n\nPatients are eligible for inclusion if they meet all of the following criteria:\n\nAge ≥18 years and ≤75 years, with no gender restrictions; Presence of a peripheral lung lesion on chest CT \\[Peripheral lung is defined as a nodule located in the fourth-order or higher airway (with the carina defined as order 0, the left and right main bronchi defined as order 1, lobar bronchi as order 2, segmental bronchi as order 3, and subsegmental bronchi as order 4)\\] in patients who require biopsy \\[2. The population requiring biopsy refers to individuals identified with an occupational lung lesion\u002Fnodule (including solid nodules, part-solid nodules, and ground-glass nodules) during clinical trial screening or with risk factors, and who, after comprehensive assessment by a clinician of the patient's clinical information, imaging, tumor markers, and functional imaging, are highly suspected of having cancerous nodules. Bronchoscopy biopsy is planned to further clarify the diagnosis and to guide staging treatment based on pathological results.\\]; Patients voluntarily agree to undergo bronchoscopy and meet the requirements for the procedure; Patients are capable of understanding the purpose of the trial, demonstrate good compliance with the examinations and follow-up, voluntarily participate in the clinical trial, and sign an informed consent form.\n\n\\-\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from this study:\n\n1.Presence of contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina; severe cardiac or pulmonary dysfunction; severe hypertension and arrhythmias; uncorrectable bleeding tendencies or severe coagulation disorders (such as platelet count \\\u003C60×10\\^9\u002FL), uremia; severe pulmonary artery hypertension; severe superior vena cava syndrome; intracranial hypertension; acute cerebrovascular events; aortic dissection or aneurysm; multiple bullae; extreme systemic exhaustion; 2.Female patients who are breastfeeding, pregnant, or planning pregnancy; 3.Patients with electromagnetic active implantable medical devices; 4.Subjects allergic to anesthetics; or with a history of multiple severe allergies, hereditary allergy history; 5.Those who have participated in or are currently participating in drug clinical trials within 3 months before screening, or have participated in other medical device clinical trials within 30 days; 6.Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.\n\n\\-","75 Years",{"count":290,"type":20},[57],"Robotic bronchoscopy represents the latest localization technology for peripheral pulmonary nodules, enabling precise and stable manipulation, thereby enhancing the diagnostic yield of peripheral lung pathologies. Its safety and feasibility have been internationally validated, with indications that it can significantly improve the overall diagnostic rate of biopsies for peripheral lung lesions. Nonetheless, the disparity in interventional auxiliary equipment and the level of technical operation is the primary cause for the significant variation in diagnostic rates of peripheral lung lesions across different regions, particularly in remote or underdeveloped areas. The advancement of 5G network technology has propelled the development of telemedicine, enabling remote diagnostics, surgeries, and real-time multi-party collaboration, which is expected to elevate the medical standards in remote areas, improve the diagnostic rate of peripheral lung lesions, and achieve homogenization of medical services. In summary, the integration of 5G with bronchoscopy is anticipated to bring breakthroughs in the diagnosis and treatment of peripheral lung pathologies.\n\nResearch Objective:\n\nThe primary objective of this clinical trial is to evaluate the safety and efficacy of the remote application of bronchoscopy systems and catheters for the localization and sampling of peripheral pulmonary nodules, under the premise of ensuring the safety of the subjects and the scientific integrity of the clinical trial, with the aid of 5G network.\n\nResearch Method:\n\nThe study is a prospective, multicenter, single-arm clinical trial with a target value design, intending to include 10 cases of individuals with peripheral pulmonary nodules who are willing to undergo intra-airway examination and sampling operations using remote bronchial navigation localization devices assisted by the 5G communication network. The safety and efficacy of the bronchial navigation localization devices and catheters for the localization and sampling of peripheral pulmonary nodules, developed by Changzhou Langhe Medical Devices Co., Ltd. (hereinafter referred to as \"Langhe Medical\"), will be assessed.\n\nAnalysis:\n\nStatistical data analysis will be performed using SAS software version 9.4 or higher.",[25],[327,328,329],"peripheral pulmonary lesions","remote bronchoscopy","robotic bronchoscopy system","2024-11-20",{"date":332,"type":36},"2024-11-22",{"date":334,"type":36},"2024-09-15",{"date":336,"type":20},"2025-02-15",{"name":338,"class":104},"Guangzhou Medical University",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":105},"100567817","respiratory-disease-cohort-studies-of-chinese-medicine-for-pulmonary-nodule-100567817","NCT06673121","Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule","Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule （RESEARCH-PN）","Inclusion Criteria:\n\n① Patients with pulmonary nodules and recommended for follow-up by MDT; ② Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n①Patients with metastatic pulmonary nodules; ②Patients with benign diseases such as pulmonary lymph nodes, hamartomas, sclerosing alveolar cell tumors, or nodules with obvious benign features such as calcification; ③Patients withserious heart, lung, liver and kidney diseases.",{"count":347,"type":20},5000,"This study is a prospective multicenter cohort study that primarily evaluates the impact of traditional Chinese medicine treatment on pulmonary nodules",[25,350,351],"Cohort Study","Traditional Chinese Medicine",[158,353,351],"Cohort study","2024-11-01",{"date":356,"type":36},"2024-11-04",{"date":358,"type":36},"2024-01-03",{"date":360,"type":20},"2029-12-30",{"name":362,"class":104},"Third Affiliated Hospital of Henan University of Traditional Chinese Medicine",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":371,"sex":16,"minAge":372,"maxAge":233,"enrollmentInfo":373,"targetDuration":4,"studyType":55,"phases":375,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":105},"100564355","improving-detection-of-early-lung-cancer-in-a-diverse-population-ideal-study-100564355","NCT06628102","Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study","Improving Detection of Early Lung Cancer in a Diverse Population","IDEAL","Inclusion Criteria:\n\nAge 50-80\n\n* Able to consent\n* Chest CT positive for nodule equal to or greater than 6mm\n* No additional other cancer- (outside of lung cancer for group 1)\n* Must be able to abstain from smoking tobacco for 24 hours prior to the breath test.\n\nExclusion Criteria:\n\n* Too sick to provide a breath sample\n* you have smoked in the last 24 hours\n* You are pregnant\n* You have been diagnosed with a respiratory infection in the last 3 months\n* Unwilling to consent to the study",true,"50 Years",{"count":374,"type":20},3600,[57],"The goal of this trial is to (a) identify people at high risk of lung cancer who would benefit from LDCT screening but are currently ineligible based on current lung cancer screening criteria (b) provide the framework to manage patients with Incidental Pulmonary Nodules (IPNs) with appropriate follow-up based on accurate interpretation of the Chest CT scan that is already available and (c) develop a simple, point-of-care, minimally invasive test, focusing on the breath and circulating blood proteins, to detect lung cancer, and develop a method to differentiate between cancerous and non-cancerous nodules using a single. Participants will be asked to answer a questionnaire regarding their age, race\u002Fethnicity, smoking history, and residential history if they have ever been told they have chronic obstructive pulmonary disease (COPD), high blood pressure, education level, medications and height and weight. Participants will then be asked to give a breath sample via the breath collection device. All this information will be collected before the breath collection. After that, participants will give 1-2 tablespoons of blood. CT scans with IPN(s) will be reviewed and run through a computer detection software to identify nodules, followed up as per current clinical guidelines.",[26,25],[379,380,381,382],"Volatile Organic Compounds","CT Scan","Screening","Biomarkers","2024-10-03",{"date":385,"type":36},"2024-10-04",{"date":387,"type":36},"2023-08-04",{"date":389,"type":20},"2028-12-31",{"name":391,"class":104},"British Columbia Cancer Agency"]